Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems

July 11, 2025

The Top 5 Biosimilar Articles for the Week of July 7

July 11, 2025

Two More Pairs of Denosumab Biosimilars Enter US Market

July 09, 2025

Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

July 08, 2025

Consumers and Providers Face Biosimilar Knowledge Hurdles

July 07, 2025

Part 1: FDA Workshop Highlights Global Regulatory View on Biosimilar Development

September 13th 2023

By Skylar Jeremias

Article

An FDA workshop featuring regulators from around the world provided the regulatory perspective on how each government determines whether a biosimilar is clinically equivalent to their reference product, highlighting the science behind their development guidelines.

AAM Report: Generics and Biosimilars Generate $408 Billion in 2022

September 12th 2023

By Skylar Jeremias

Article

A report from the Association for Accessible Medicines (AAM) highlighted the value of biosimilars and generics, revealing that lower-cost versions of originator products accumulated $408 billion for the US health care system in 2022.

Link Between Antidrug Antibodies and bDMARDs Nonresponse in Patients With RA

September 11th 2023

By Justina Petrullo

Article

Study results suggest an association between antidrug antibodies and nonresponse to biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA).

Fran Gregory Weighs In on the Value of Interchangeability in the Adalimumab Market

September 10th 2023

By Skylar Jeremias

Video

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, explains the value of interchangeability in the adalimumab space and predicts whether interchangeable biosimilars will become leaders in adoption.

Regulatory Updates From Around the Globe Provide Hope for Biosimilars

September 9th 2023

By Skylar Jeremias

Article

An approval in Australia and positive recommendations for 2 biosimilars in Europe bring hope for more affordable biologics around the world. However, another settlement for a US ustekinumab biosimilar showcases that some barriers remain.

The Top 5 Biosimilar Articles for the Week of September 4

September 8th 2023

By Justina Petrullo

Video

Here are the top 5 biosimilar articles for the week of September 4, 2023.

The Growth of Biosimilars Continues to Create Hope for Lower Drug Costs

September 7th 2023

By Luke Halpern

Article

Perhaps the most significant development in the pharmaceutical industry in decades, crops of biosimilars are being approved and are ready for distribution. What lies next, in terms of legislation and the impact on pharmacists, remains to be seen.

CVS Launches New Biosimilars Brand

September 6th 2023

By Skylar Jeremias

Article

CVS Health Corporation launched Cordavis, a new subsidiary that will work with manufacturers to commercialize and coproduce biosimilars, beginning with an adalimumab product.

Biosimilars Business Roundup For August 2023—Podcast Edition

September 5th 2023

By Justina Petrullo

Podcast

On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.

Higher Risk of Discontinuation During Biosimilar Switching Found Among Women

September 5th 2023

By Justina Petrullo

Article

Switching from reference to biosimilar adalimumab was found to be safe and effective. Researchers cautioned that female patients may be at higher risk of discontinuation compared with their male counterparts.